-
After 20 years and $200 billion in revenue, Humira — an injectable treatment for autoimmune conditions like rheumatoid arthritis — is losing its monopoly.
-
Drugs made from proteins or antibodies are difficult for rival manufacturers to copy. The Food and Drug Administration just approved a copycat drug for cancer patients that shows it can be done.